Abstract:Patient-level health economic data collected alongside clinical trials are an important component of the process of technology appraisal. For end-of-life treatments, the modeling of cost-effectiveness data may involve some form of partitioned survival analysis, in which measures of quality of life and survival for pre- and postprogression periods are combined to generate aggregate measures of clinical benefits (e.g., quality-adjusted survival). In addition, resource use data are often collected and costs are calculated for each type of health service (e.g., treatment, hospital, or adverse events costs). A critical problem in these analyses is that effectiveness and cost data present some complexities, such as nonnormality, spikes, and missingness, which should be addressed using appropriate methods to avoid biased results. This article proposes a general Bayesian framework that takes into account the complexities of trial-based partitioned survival cost-utility data to provide more adequate evidence for policy makers. Our approach is motivated by, and applied to, a working example based on data from a trial assessing the cost-effectiveness of a new treatment for patients with advanced non–small-cell lung cancer. Highlights • This is the first article proposing a Bayesian modeling framework for patient-level partitioned survival cost-utility analysis that can jointly take into account the typical complexities of the data, such as correlation, skewness, and spikes at zeros. • The framework is defined using a modular structure that enables a flexible model specification in terms of a sequence of conditional parametric distributions that can be chosen based on the specific characteristics of each modeled variable (e.g., type of effectiveness or cost component). • The proposed methods overcome the limitations of standard approaches that ignore at least some of the complexities of the data and, although easier to implement and well established among practitioners, may mislead cost-effectiveness decisions of policy makers. Social media content • Draft Tweet: The article proposes a new modeling Bayesian framework for trial-based partitioned survival cost-utility analysis that can flexibly take into account the impact of different sources of uncertainty on cost-effectiveness conclusions • Twitter's account name: Andrea Gabrio (@AndreaGabrio) • Preferred tags: #CostEffectiveness; #BayesianStatistics, #EconomicEvaluation

A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies

Bayesian Nonparametric Cost-Effectiveness Analyses: Causal Estimation and Adaptive Subgroup Discovery

Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation

A regression framework for a probabilistic measure of cost-effectiveness

Decision Curve Analysis: a Technical Note

An efficient approach for optimizing the cost-effective individualized treatment rule using conditional random forest

Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies

The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study

Calculating the Expected Net Benefit of Sampling for Survival Data: A Tutorial and Case Study

A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases

Benchmarking Observational Studies with Experimental Data under Right-Censoring

An Inverse Probability Weighted Regression Method that Accounts for Right-censoring for Causal Inference with Multiple Treatments and a Binary Outcome

Learning Robust Treatment Rules for Censored Data

Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation.

A stochastic framework for estimation of summary measures in cost-effectiveness analyses.

Seemingly unrelated Bayesian additive regression trees for cost-effectiveness analyses in healthcare

Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve

Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests

Sampling with censored data: a practical guide

A framework for understanding selection bias in real-world healthcare data